Join us on October 8 for a lively discussion on the Telemedicine Cliff – Approaches for Navigating to the Other Side of the Public Health Emergency (PHE).
During our conversation, we will:
- Learn the high–risk areas to consider as we near the end of the PHE
- Identify how to prepare if we revert back to the pre–COVID laws
- Understand how to determine what may, or may not, change at the end of the PHE
- Forecast options for post–COVID opportunities with Telemedicine
In case you missed it, you can listen to the 3rd annual Let’s Talk Compliance program in its entirety for free, and download slides from each of the sessions, by clicking here, and be sure to check out the following Let’s Talk Compliance additional resources:
- Master Class Key Takeaways Blog
- HIPAA Breach & Penalties Webinar & Key Takeaway Blog
- Provider Relief Fund: Reporting Requirements and Compliance Concerns Webinar & Key Takeaway Blog
We are working on developing future Let’s Talk Compliance events, so stay tuned for dates and details!
People
Related Insights
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
April 14, 2026
Foley Career Perspectives
Trust Your Instincts: Susan Pravda on Leadership, Relationships, and Resilience
Foley partner Susan Pravda is a business lawyer focused on mergers and acquisitions, venture capital, initial public offerings, and related securities transactions and is head of Foley’s Health Care & Life Sciences Sector. She also serves as the firm’s chief strategic talent acquisition partner.
April 14, 2026
Blogs
When to Litigate and When to Walk Away
Clients faced with defending or initiating litigation often begin with the question: “Can we win?” The question sounds simple enough, and if the law is favorable, the instinctive answer might be “yes.” But “winning” in court doesn’t happen, and can’t be evaluated, in a vacuum. In reality, the odds of success in litigation depend not only on the law and facts of the case but also on any business constraints and potential consequences.